X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2062) 2062
Book Review (289) 289
Publication (87) 87
Conference Proceeding (16) 16
Book Chapter (6) 6
Dissertation (4) 4
Web Resource (3) 3
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1425) 1425
humans (1363) 1363
esomeprazole (1243) 1243
male (906) 906
female (862) 862
omeprazole (724) 724
proton pump inhibitors (714) 714
gastroenterology & hepatology (703) 703
middle aged (679) 679
adult (638) 638
pharmacology & pharmacy (548) 548
treatment outcome (498) 498
aged (457) 457
gastroesophageal reflux - drug therapy (416) 416
esomeprazole - therapeutic use (412) 412
proton pump inhibitors - therapeutic use (371) 371
lansoprazole (359) 359
esomeprazole - administration & dosage (353) 353
anti-ulcer agents - therapeutic use (299) 299
gastroesophageal reflux (279) 279
rabeprazole (262) 262
gastroesophageal-reflux disease (258) 258
proton pump inhibitor (226) 226
helicobacter pylori (225) 225
therapy (223) 223
pantoprazole (222) 222
proton pump inhibitors - administration & dosage (215) 215
anti-ulcer agents - administration & dosage (214) 214
drug therapy, combination (214) 214
esomeprazole - adverse effects (206) 206
helicobacter infections - drug therapy (201) 201
management (200) 200
adolescent (194) 194
double-blind method (188) 188
pharmacokinetics (188) 188
young adult (184) 184
prospective studies (182) 182
double-blind (177) 177
proton pump inhibitors - adverse effects (177) 177
symptoms (177) 177
gastroesophageal reflux disease (176) 176
efficacy (174) 174
erosive esophagitis (171) 171
medicine & public health (163) 163
dose-response relationship, drug (156) 156
medicine, general & internal (156) 156
aged, 80 and over (155) 155
care and treatment (150) 150
drug administration schedule (148) 148
hydrogen-ion concentration (148) 148
esophagitis (143) 143
gerd (136) 136
omeprazole - therapeutic use (136) 136
abridged index medicus (128) 128
internal medicine (126) 126
risk factors (125) 125
drug therapy (121) 121
disease (119) 119
time factors (118) 118
anti-bacterial agents - therapeutic use (116) 116
clinical trials (116) 116
drug interactions (116) 116
esomeprazole - pharmacology (114) 114
metaanalysis (114) 114
gastroesophageal reflux - complications (113) 113
heartburn (111) 111
infection (111) 111
proton pump inhibitors - pharmacology (110) 110
administration, oral (109) 109
cross-over studies (109) 109
anti-ulcer agents - adverse effects (108) 108
risk (107) 107
pharmacology/toxicology (106) 106
quality-of-life (100) 100
helicobacter pylori - drug effects (99) 99
prevalence (99) 99
proton-pump inhibitors (98) 98
dosage and administration (97) 97
eradication (97) 97
gastroesophageal reflux - diagnosis (97) 97
2-pyridinylmethylsulfinylbenzimidazoles (96) 96
health aspects (95) 95
severity of illness index (95) 95
diagnosis (91) 91
esomeprazole 40 mg (91) 91
animals (89) 89
omeprazole - administration & dosage (89) 89
research (89) 89
amoxicillin (88) 88
clarithromycin (88) 88
aspirin (87) 87
amoxicillin - therapeutic use (86) 86
endoscopy (86) 86
esophagitis, peptic - drug therapy (86) 86
analysis (85) 85
gastric acid - secretion (85) 85
triple therapy (84) 84
anti-ulcer agents - pharmacology (81) 81
intragastric ph (81) 81
gastroesophageal-reflux (80) 80
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1925) 1925
French (33) 33
German (33) 33
Spanish (20) 20
Russian (18) 18
Chinese (16) 16
Korean (14) 14
Japanese (6) 6
Czech (3) 3
Dutch (3) 3
Italian (3) 3
Portuguese (3) 3
Swedish (3) 3
Hungarian (2) 2
Polish (2) 2
Bulgarian (1) 1
Danish (1) 1
Norwegian (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


10/2011
Objective : Present study was carried out to evaluate effect of esomeprazole on the pharmacokinetics of carbamazepine in rabbits. Materials and Methods : Study... 
esomeprazole | pharmacokinetics | Carbamazepine
Web Resource
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 03/2015, Volume 41, Issue 6, pp. 581 - 589
Journal Article
07/2013
Purpose: To prepare and evaluate in vitro mucoadhesive esomeprazole magnesium microspheres for the treatment of Zollinger Ellison syndrome. Methods: The... 
Microspheres | Esomeprazole magnesium | Spray drying | Sustained release
Web Resource
Journal of Pediatric Gastroenterology and Nutrition, ISSN 0277-2116, 09/2017, Volume 65, Issue 3, pp. 272 - 277
Journal Article
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 12/2013, Volume 28, Issue 12, pp. 1823 - 1828
Journal Article
by Mastronarde, John G and Anthonisen, Nicholas R and Castro, Mario and Holbrook, Janet T and Leone, Frank T and Teague, W. Gerald and Wise, Robert A and Hanania, N.A and Sockrider, M and Giraldo, L and Valdez, R and Flores, E and Reibman, J and DiMango, E and Rogers, L and Cammarata, C and Carapetyan, K and Sormillon, J and Simpson, E and Williams, L and Sundy, J and Dudek, G and Newton, R and Dugdale, A and Teague, W.G and Fitzpatrick, A and Khatri, S and Patel, R and Peabody, J and Hunter, E and Whitlock, D and Smith, L and Moy, J and Naureckas, E and Olopade, C.S and Hixon, J and Brees, A and Rivera, G and Sietsema, S and Zagaja, V and Busk, M and Williams, C and Puntenney, P and Busk, N and Leone, F and Hayes-Hampton, M and Summer, W.R and Meyaski, G and Wenzel, S and Katial, R and Lopez, L and Lima, J and Blake, K and Santos, A and Vega, K and Lambiase, L and Langford, T and Schaeffer, D and Lang, J and McRae, M and Karpel, J and Cohen, R and Ramdeo, R and Irvin, C.G and Dixon, A.E and Kaminsky, D.A and Colletti, R and Burns, S.M and Bourassa, L.M and Lang, S.E and Griffes, L.V and Pratt, R and Nakos, K.B and Girard, K.J and Mastronarde, J and McCoy, K and Parsons, J and Drake, J and Compton, R and Raterman, L and Cosmar, D and Gerald, L.B and Bailey, W.C and Erwin, S and Kelley, A and Laken, D and Wanner, A and Lockey, R and Mendes, E and McCullough, S and Fimbel, B and Grandstaff, M and Blumenthal, Malcolm N and Brottman, G and Hagen, J and Decker, A and Lascewski, D and Kelleher, S and Bachman, K and Quintard, C and ... and The American Lung Association Asthma Clinical Research Centers and Amer Lung Assoc Asthma Clinical Re and American Lung Association Asthma Clinical Research Centers
The New England Journal of Medicine, ISSN 0028-4793, 04/2009, Volume 360, Issue 15, pp. 1487 - 1499
Journal Article
Circulation, ISSN 0009-7322, 08/2013, Volume 128, Issue 8, pp. 845 - 853
BACKGROUND—Proton pump inhibitors (PPIs) are gastric acid–suppressing agents widely prescribed for the treatment of gastroesophageal reflux disease. Recently,... 
dimethylarginine dimethylaminohydrolase | endothelium | proton pump inhibitors | nitric oxide | N,N dimethylarginine | N dimethylarginine | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | ENDOTHELIAL DYSFUNCTION | MYOCARDIAL-INFARCTION | NITRIC-OXIDE SYNTHASE | ACID SUPPRESSION | ADMA | DIMETHYLAMINOHYDROLASE DDAH | PERIPHERAL VASCULAR DISEASE | CORONARY-HEART-DISEASE | STAGE RENAL-DISEASE | ARTERY-DISEASE | Proton Pump Inhibitors - pharmacology | Humans | Esomeprazole - adverse effects | Esomeprazole - pharmacology | Endothelium, Vascular - drug effects | Male | Arginine - analogs & derivatives | Esomeprazole - therapeutic use | Cardiovascular Diseases - epidemiology | Nitric Oxide Synthase Type III - metabolism | Gastroesophageal Reflux - drug therapy | Disease Models, Animal | Amidohydrolases - metabolism | Proton Pump Inhibitors - adverse effects | Cardiovascular Diseases - metabolism | Mice, Inbred C57BL | Risk Factors | Cells, Cultured | Biomarkers - blood | Proton Pump Inhibitors - therapeutic use | Animals | Lansoprazole - adverse effects | Endothelium, Vascular - metabolism | Arginine - blood | Lansoprazole - pharmacology | Endothelium, Vascular - pathology | Mice | Vasodilation - drug effects | Lansoprazole - therapeutic use | Gastroesophageal reflux | Complications and side effects | Usage | Care and treatment | Patient outcomes | Proton pump inhibitors | Cardiovascular diseases | Drug therapy | Health aspects | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 05/2016, Volume 43, Issue 10, pp. 1048 - 1059
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 07/2015, Volume 9, Issue default, pp. 4127 - 4135
Background: HCP1004 is a newly developed fixed-dose combination of naproxen (500 mg) and esomeprazole strontium (20 mg) that is used in the treatment of... 
Naproxen/esomeprazole | Drug development | Comparative pharmacokinetics | GASTRIC-ULCERS | CHEMISTRY, MEDICINAL | comparative pharmacokinetics | THERAPY | drug development | RISK | PHARMACOLOGY & PHARMACY | PHARMACOGENETICS | COMPLICATIONS | naproxen/esomeprazole | ENTERIC-COATED NAPROXEN | Esomeprazole - administration & dosage | Area Under Curve | Humans | Middle Aged | Esomeprazole - adverse effects | Half-Life | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Esomeprazole - chemistry | Male | Metabolic Clearance Rate | Esomeprazole - blood | Healthy Volunteers | Anti-Inflammatory Agents, Non-Steroidal - blood | Young Adult | Proton Pump Inhibitors - administration & dosage | Naproxen - pharmacokinetics | Naproxen - administration & dosage | Adult | Proton Pump Inhibitors - blood | Republic of Korea | Naproxen - adverse effects | Proton Pump Inhibitors - adverse effects | Administration, Oral | Esomeprazole - pharmacokinetics | Naproxen - blood | Chemistry, Pharmaceutical | Naproxen - chemistry | Cross-Over Studies | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Proton Pump Inhibitors - chemistry | Proton Pump Inhibitors - pharmacokinetics | Models, Biological | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Drug Combinations | Plasma | Compliance | Sample size | Medical services | Arthritis | Strontium | Confidence intervals | Naproxen | Standard deviation | Magnesium | Safety | Nonsteroidal anti-inflammatory drugs | Drug therapy | Drug dosages | Food | Medical treatment | Rheumatic diseases | Health risks | Risk reduction | Pharmacology | Inflammation | Bioavailability | Crossovers | Nonsteroidal antiinflammatory drugs | Omeprazole | Ulcers | Internet | Pharmacokinetics | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 6/2013, Volume 71, Issue 6, pp. 1635 - 1643
The metabolism of pazopanib is primarily mediated by CYP3A4. The solubility of pazopanib is pH-dependent, and an elevated gastric pH may decrease its... 
Medicine & Public Health | Ketoconazole | Esomeprazole | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | CYP3A4 | Pazopanib | RABEPRAZOLE | HEALTHY-SUBJECTS | 24-H | TRIAL | ONCOLOGY | PHARMACOLOGY & PHARMACY | INHIBITOR | PHASE-I | DRUG-INTERACTION |